NCT04205643View on ClinicalTrials.gov

CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Ulcerative Colitis (LIBERTY-UC)

PHASE3CompletedINTERVENTIONAL
Enrollment

548

Participants

Timeline

Start Date

September 1, 2020

Primary Completion Date

July 7, 2022

Study Completion Date

July 11, 2023

Conditions
Ulcerative Colitis
Interventions
BIOLOGICAL

CT-P13 SC (Infliximab)

Subcutaneous injection of CT-P13 SC

OTHER

Placebo SC

Subcutaneous injection of Placebo SC

Trial Locations (1)

00-728

Centrum Zdrowia MDM, Warsaw

Sponsors

Lead Sponsor

Celltrion
All Listed Sponsors
lead

Celltrion

INDUSTRY